Loading...
SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
INTRODUCTION: Since 2008 United State (US) food drug administration mandate, several newer anti-diabetic drugs (ADD) have undergone a mandatory cardiovascular (CV) outcome trial (CVOT) in type diabetes (T2DM) patients with high CV risk. These includes CVOT done with dipeptidyl-peptidase-4 inhibitors...
Saved in:
| Published in: | Indian J Endocrinol Metab |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Wolters Kluwer - Medknow
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6540886/ https://ncbi.nlm.nih.gov/pubmed/31161099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijem.IJEM_12_19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|